Avalo Therapeutics, Inc. (AVTX) Tops Q3 EPS by 99c

Avalo Therapeutics, Inc. (NASDAQ: AVTX) reported Q3 EPS of ($0.11), $0.99 better than the analyst estimate of ($1.10). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $1 million.

For earnings history and earnings-related data on Avalo Therapeutics, Inc. (AVTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c